Muscarinic Cholinergic Receptor Measurements with [18F]FP-TZTP: Control and Competition Studies
- 1 October 1998
- journal article
- research article
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 18 (10) , 1130-1142
- https://doi.org/10.1097/00004647-199810000-00010
Abstract
[18F]Fluoropropyl-TZTP (FP-TZTP) is a subtype-selective muscarinic cholinergic ligand with potential suitability for studying Alzheimer's disease. Positron emission tomography studies in isofluorane-anesthetized rhesus monkeys were performed to assess the in vivo behavior of this radiotracer. First, control studies (n = 11) were performed to characterize the tracer kinetics and to choose an appropriate model using a metabolite-corrected arterial input function. Second, preblocking studies (n = 4) with unlabeled FP-TZTP were used to measure nonspecific binding. Third, the sensitivity of [18F]FP-TZTP binding to changes in brain acetylcholine (ACh) was assessed by administering physostigmine, an acetylcholinesterase (AChE) inhibitor, by intravenous infusion (100 to 200 μg·kg−1·h−1) beginning 30 minutes before tracer injection (n = 7). Tracer uptake in the brain was rapid with K1 values of 0.4 to 0.6 mL·min−1·mL−1 in gray matter. A model with one tissue compartment was chosen because reliable parameter estimates could not be obtained with a more complex model. Volume of distribution ( V) values, determined from functional images created by pixel-by-pixel fitting, were very similar in cortical regions, basal ganglia, and thalamus, but significantly lower ( P < 0.01) in the cerebellum, consistent with the distribution of M2 cholinergic receptors. Preblocking studies with unlabeled FP-TZTP reduced V by 60% to 70% in cortical and subcortical regions. Physostigmine produced a 35% reduction in cortical specific binding ( P < 0.05), consistent with increased ACh competition. The reduction in basal ganglia (12%) was significantly smaller ( P < 0.05), consistent with its markedly higher AChE activity. These studies indicate that [18F]FP-TZTP should be useful for the in vivo measurement of muscarinic receptors with positron emission tomography.Keywords
This publication has 27 references indexed in Scilit:
- Quantification of Amphetamine-Induced Changes in [11C]Raclopride Binding with Continuous InfusionJournal of Cerebral Blood Flow & Metabolism, 1997
- Muscarinic Signaling in the Central Nervous SystemAnesthesiology, 1996
- Comparison of Methods for Analysis of Clinical [11C]Raclopride StudiesJournal of Cerebral Blood Flow & Metabolism, 1996
- Synthesis, in vivo biodistribution and dosimetry of [11C]N-Methylpiperidyl benzilate ([11C]NMPB), a muscarinic acetylcholine receptor antagonistNuclear Medicine and Biology, 1995
- Comparison of Bolus and Infusion Methods for Receptor Quantitation: Application to [18F]Cyclofoxy and Positron Emission TomographyJournal of Cerebral Blood Flow & Metabolism, 1993
- Compartmental Analysis of [11C]Flumazenil Kinetics for the Estimation of Ligand Transport Rate and Receptor Distribution Using Positron Emission TomographyJournal of Cerebral Blood Flow & Metabolism, 1991
- Age‐related decreases in muscarinic cholinergic receptor binding in the human brain measured with positron emission tomography (PET)Journal of Neuroscience Research, 1990
- Brain regional distribution of physostigmine and its relation to cerebral blood flow following intravenous administration in ratsJournal of Neuroscience Research, 1990
- Kinetic Analysis of Central [11C]Raclopride Binding to D2-Dopamine Receptors Studied by PET—A Comparison to the Equilibrium AnalysisJournal of Cerebral Blood Flow & Metabolism, 1989
- Evaluation of Regional Differences of Tracer Appearance Time in Cerebral Tissues Using [15O]Water and Dynamic Positron Emission TomographyJournal of Cerebral Blood Flow & Metabolism, 1988